| Susan Renee Garwood, MD | |
|
6 Hampden Pl, Utica, NY 13502-5631 | |
| (315) 624-3666 | |
| Not Available |
| Full Name | Susan Renee Garwood |
|---|---|
| Gender | Female |
| Speciality | Infectious Disease |
| Experience | 39 Years |
| Location | 6 Hampden Pl, Utica, New York |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053381921 | NPI | - | NPPES |
| 5859 | Other | NC | PARTNERS MEDICARE CHOICE |
| 8934773 | Medicaid | NC | |
| C2464 | Other | NC | MEDCOST |
| EFF | Other | NC | CIGNA HEALTHCARE |
| 34773 | Other | NC | BCBSNC |
| 4378353 | Other | NC | AETNA |
| 440004085 | Other | NC | RAILROAD MEDICARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RI0200X | Internal Medicine - Infectious Disease | 32702 (North Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Vincent Healthcare | Billings, MT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Scl Health Medical Group - Billings Llc | 9638491574 | 219 |
News Archive
Renishaw's novel drug delivery system, to be used in partnership with Herantis Pharma Plc's drug candidate CDNF for the treatment of Parkinson's disease, is about to enter phase 1-2 clinical trials. The study will be supported by a €6 million grant from Horizon 2020, the European Union's Framework Programme for Research and Innovation.
A Ludwig Cancer Research study has dissected how radiotherapy alters the behavior of immune cells known as macrophages found in glioblastoma (GBM) tumors and shown how these cells might be reprogrammed with an existing drug to suppress the invariable recurrence of the aggressive brain cancer.
Leading experts treating COVID-19 patients provide advice on managing cardiovascular disease during the pandemic.
A Norwegian study offers further evidence to support the use of intravenous thrombolysis to treat stroke even in patients with contraindications to the drug.
› Verified 8 days ago
| Entity Name | Scl Health Medical Group - Billings Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508289703 PECOS PAC ID: 9638491574 Enrollment ID: O20141204001495 |
News Archive
Renishaw's novel drug delivery system, to be used in partnership with Herantis Pharma Plc's drug candidate CDNF for the treatment of Parkinson's disease, is about to enter phase 1-2 clinical trials. The study will be supported by a €6 million grant from Horizon 2020, the European Union's Framework Programme for Research and Innovation.
A Ludwig Cancer Research study has dissected how radiotherapy alters the behavior of immune cells known as macrophages found in glioblastoma (GBM) tumors and shown how these cells might be reprogrammed with an existing drug to suppress the invariable recurrence of the aggressive brain cancer.
Leading experts treating COVID-19 patients provide advice on managing cardiovascular disease during the pandemic.
A Norwegian study offers further evidence to support the use of intravenous thrombolysis to treat stroke even in patients with contraindications to the drug.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Susan Renee Garwood, MD 2209 Genesee St, Business Office Room 315, Utica, NY 13501-5930 Ph: (315) 801-8534 | Susan Renee Garwood, MD 6 Hampden Pl, Utica, NY 13502-5631 Ph: (315) 624-3666 |
News Archive
Renishaw's novel drug delivery system, to be used in partnership with Herantis Pharma Plc's drug candidate CDNF for the treatment of Parkinson's disease, is about to enter phase 1-2 clinical trials. The study will be supported by a €6 million grant from Horizon 2020, the European Union's Framework Programme for Research and Innovation.
A Ludwig Cancer Research study has dissected how radiotherapy alters the behavior of immune cells known as macrophages found in glioblastoma (GBM) tumors and shown how these cells might be reprogrammed with an existing drug to suppress the invariable recurrence of the aggressive brain cancer.
Leading experts treating COVID-19 patients provide advice on managing cardiovascular disease during the pandemic.
A Norwegian study offers further evidence to support the use of intravenous thrombolysis to treat stroke even in patients with contraindications to the drug.
› Verified 8 days ago
Elif N Erim, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 2150 Bleecker St, Utica, NY 13501 Phone: 315-798-4955 Fax: 315-798-4740 | |
Nalini J Namassivaya, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 35 Riverside Dr, Utica, NY 13502 Phone: 315-735-2294 Fax: 315-735-2021 | |
Dr. Bradley Sklar, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 116 Business Park Drive, 1st Floor, Utica, NY 13502 Phone: 315-624-7000 Fax: 315-793-1129 | |
Tracey Elizabeth Beard Hansel, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1656 Champlin Ave, Utica, NY 13502 Phone: 315-624-6467 Fax: 315-624-6469 | |
Emile Wassel, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1450 Champlin Ave Ste 1, Utica, NY 13502 Phone: 315-624-9004 Fax: 315-624-9003 | |
Stanley Weiselberg, M.D. Infectious Disease Medicare: Medicare Enrolled Practice Location: 116 Business Park Drive, 1st Floor, Utica, NY 13502 Phone: 315-624-7000 Fax: 315-793-1129 |